Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 7/20 | 0.62 |
| ▸ | CHRNA4 | P43681 | 7/20 | 0.62 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.62 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.62 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.62 |
| ▸ | ESR1 | P03372 | 1/20 | 0.62 |
| ▸ | CHRNG | P07510 | 1/20 | 0.62 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.62 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.62 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.62 |
| ▸ | HTR3A | P46098 | 1/20 | 0.62 |
| ▸ | CHRND | Q07001 | 1/20 | 0.62 |
| ▸ | CHRNA2 | Q15822 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KDM5A | P29375 | 1/20 | 0.31 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13561408 | 1.00 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL10025840 | 0.80 | CHRNB4 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL14003841 | 0.77 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL29363551 | 0.77 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL5959022 | 0.77 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL29710884 | 0.77 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL225687 | 0.77 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL137144 | 0.77 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL2615185 | 0.76 | CHRNB4 (0.39) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL31413921 | 0.75 | CHRNB4 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285407-A1 | VARENICILINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2023-09-14 | — | — | US | disclosed |
| US-20130101630-A1 | HIGHLY PURE VARENICLINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF SUBSTANTIALLY FREE OF METHYLVARENICLINE IMPURITY | ACTAVIS GROUP PTC EHF (IS) | 2013-04-25 | — | — | US | disclosed |
| US-20130072682-A1 | PROCESS FOR PREPARING VARENICLINE, VARENICLINE INTERMEDIATES, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2013-03-21 | — | — | US | disclosed |
| US-8314235-B2 | Process for preparing varenicline, varenicline intermediates, pharmaceutically acceptable salts thereof | ACTAVIS GROUP PTC EHF (IS) | 2012-11-20 | — | — | US | disclosed |
| US-8178537-B2 | Solid state forms of varenicline salts and processes for preparation thereof | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2012-05-15 | — | — | US | disclosed |
| US-20120093887-A1 | AMORPHOUS VARENICLINE TARTRATE CO-PRECIPITATES | ACTAVIS GROUP PTC EHF (IS) | 2012-04-19 | — | — | US | disclosed |
| US-20110224437-A1 | PROCESS FOR PREPARING VARENICLINE, VARENICLINE INTERMEDIATES, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2011-09-15 | — | — | US | disclosed |
| US-20110086086-A1 | TRANSDERMAL SYSTEM FOR VARENICLINE | PFIZER INC | 2011-04-14 | — | — | US | disclosed |
| US-20100324055-A1 | SOLID STATES FORMS OF VARENICLINE SALTS AND PROCESSES FOR PREPARATION THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. | 2010-12-23 | — | — | US | disclosed |
| US-7771748-B2 | Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene | PFIZER INC (US) | 2010-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224437-A1 | PROCESS FOR PREPARING VARENICLINE, VARENICLINE INTERMEDIATES, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | TET2, NOX4, CYP3A7 | CHRNB2 114/4885CHRNA4 167/4885CHRNB4 296/4885 |
| US-20230285407-A1 | VARENICILINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | COMT, CYP2C9, CYP3A7 | CHRNB2 88/4885CHRNA4 82/4885CHRNB4 101/4885 |
| US-20130072682-A1 | PROCESS FOR PREPARING VARENICLINE, VARENICLINE INTERMEDIATES, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | TET2, NOX4, CYP3A7 | CHRNB2 114/4885CHRNA4 167/4885CHRNB4 296/4885 |
| US-20100324055-A1 | SOLID STATES FORMS OF VARENICLINE SALTS AND PROCESSES FOR PREPARATION THEREOF | SPIN2B, CACNA1S, VARS1 | CHRNB2 142/4885CHRNA4 72/4885CHRNB4 155/4885 |
| US-20130101630-A1 | HIGHLY PURE VARENICLINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF SUBSTANTIALLY FREE OF METHYLVARENICLINE IMPURITY | PDE7A, CHRNA7, HTR7 | CHRNB2 52/4885CHRNA4 48/4885CHRNB4 102/4885 |
| US-20110086086-A1 | TRANSDERMAL SYSTEM FOR VARENICLINE | CHRNA7, CACNA1G, CACNA1S | CHRNB2 35/4885CHRNA4 31/4885CHRNB4 42/4885 |
| US-20120093887-A1 | AMORPHOUS VARENICLINE TARTRATE CO-PRECIPITATES | VCL, SI, PPP2CA | CHRNB2 376/4885CHRNA4 323/4885CHRNB4 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.